Cancer Letters
Volume 276, Issue 2 , Pages 171-179 , 18 April 2009

S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor

  • Mei-Hong Li

      Affiliations

    • Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, United States
    • Department of Surgery, Division of Urology, Connecticut Children’s Medical Center, Suite 2E, 282 Washington Street, Hartford, CT 06106, United States
    • ,
  • Teresa Sanchez

      Affiliations

    • Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, United States
    • ,
  • Harold Yamase

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, CT 06030, United States
    • ,
  • Timothy Hla

      Affiliations

    • Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, United States
    • ,
  • Myat Lin Oo

      Affiliations

    • Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, United States
    • ,
  • Anna Pappalardo

      Affiliations

    • Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, United States
    • Department of Surgery, Division of Urology, Connecticut Children’s Medical Center, Suite 2E, 282 Washington Street, Hartford, CT 06106, United States
    • ,
  • Kevin R. Lynch

      Affiliations

    • Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, United States
    • ,
  • Chen-Yong Lin

      Affiliations

    • Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, United States
    • ,
  • Fernando Ferrer

      Affiliations

    • Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, United States
    • Department of Surgery, Division of Urology, Connecticut Children’s Medical Center, Suite 2E, 282 Washington Street, Hartford, CT 06106, United States
    • Corresponding Author InformationCorresponding author. Address: Department of Surgery, Division of Urology, Connecticut Children’s Medical Center, Suite 2E, 282 Washington Street, Hartford, CT 06106, United States. Tel.: +1 860 545 9658; fax: +1 860 545 9545.

Received 16 July 2008 ,Revised 19 September 2008 ,Accepted 7 November 2008.

References 

  1. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the national Wilms tumor study group. J. Clin. Oncol. 2005;23:7312–7321
  2. Benoist MR, Lemerle J, Jean R, Rufin P, Scheinmann P, Paupe J. Effects of pulmonary function of whole lung irradiation for Wilm’s tumour in children. Thorax. 1982;37:175–180
  3. Egeler RM, Wolff JE, Anderson RA, Coppes MJ. Long-term complications and post-treatment follow-up of patients with Wilms’ tumor. Semin. Urol. Oncol. 1999;17:55–61
  4. Green DM, Peabody EM, Nan B, Peterson S, Kalapurakal JA, Breslow NE. Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor study group. J. Clin. Oncol. 2002;20:2506–2513
  5. Othman F, Guo CY, Webber C, Atkinson SA, Barr RD. Osteopenia in survivors of Wilms tumor. Int. J. Oncol. 2002;20:827–833
  6. Paulino AC, Wen BC, Brown CK, Tannous R, Mayr NA, Zhen WK, et al. Late effects in children treated with radiation therapy for Wilms’ tumor. Int. J. Radiat. Oncol. Biol. Phys. 2000;46:1239–1246
  7. Scheibel-Jost P, Pfeil J, Niethard FU, Fromm B, Willich E, Kuttig H. Spinal growth after irradiation for Wilm’s tumour. Int. Orthop. 1991;15:387–391
  8. Trebo MM, Mann G, Dworzak M, Zoubek A, Gadner H. Wilms tumor and cardiomyopathy. Med. Pediatr. Oncol. 2003;41:574
  9. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids–receptor revelations. Science. 2001;294:1875–1878
  10. Lepley D, Paik JH, Hla T, Ferrer F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 2005;65:3788–3795
  11. Van Brocklyn JR, Young N, Roof R. Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett. 2003;199:53–60
  12. Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, Nagawa H, et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem. 2003;278:32841–32851
  13. Yamaguchi H, Kitayama J, Takuwa N, Arikawa K, Inoki I, Takehara K, et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem. J. 2003;374:715–722
  14. Alami J, Williams BR, Yeger H. Derivation and characterization of a Wilms’ tumour cell line, WiT 49. Int. J. Cancer. 2003;107:365–374
  15. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 2007;282:9082–9089
  16. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 2003;278:47281–47290
  17. Paik JH, Chae S, Lee MJ, Thangada S, Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J. Biol. Chem. 2001;276:11830–11837
  18. Balthasar S, Samulin J, Ahlgren H, Bergelin N, Lundqvist M, Toescu EC, et al. Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells. Biochem. J. 2006;398:547–556
  19. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301–312
  20. Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, Osada M, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J. Surg. Res. 2006;130:80–87
  21. Foss FW, Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, et al. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg. Med. Chem. 2007;15:663–677
  22. Baudhuin LM, Cristina KL, Lu J, Xu Y. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol. Pharmacol. 2002;62:660–671
  23. Taha TA, Argraves KM, Obeid LM. Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim. Biophys. Acta. 2004;1682:48–55
  24. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim. Biophys. Acta. 2002;1582:112–120
  25. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler. Thromb. Vasc. Biol. 2007;27:1312–1318
  26. Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J. Biol. Chem. 1990;265:9308–9313
  27. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 2003;4:397–407
  28. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate is essential for vascular maturation. J. Clin. Invest. 2000;106:951–961
  29. Endo A, Nagashima K, Kurose H, Mochizuki S, Matsuda M, Mochizuki N. Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII. J. Biol. Chem. 2002;277:23747–23754
  30. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 2004;4:1019–1025
  31. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 2004;15:513–520
  32. Park KS, Kim MK, Lee HY, Kim SD, Lee SY, Kim JM, et al. S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells. Biochem. Biophys. Res. Commun. 2007;356:239–244
  33. LaMontagne K, Littlewood-Evans A, Schnell C, O’Reilly T, Wyder L, Sanchez T, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66:221–231
  34. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006;9:225–238
  35. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol. Cell Biol. 2003;23:1534–1545
  36. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006;355:1124–1140

PII: S0304-3835(08)00898-7

doi: 10.1016/j.canlet.2008.11.025

Cancer Letters
Volume 276, Issue 2 , Pages 171-179 , 18 April 2009

Article Tools

* Image Usage & Resolution